Updated:
Thiogenesis Therapeutics, Corp.
Thiogenesis Therapeutics, Corp. is a Canadian biotech developing NRF2-targeting drugs for pediatric neurodevelopmental disorders, including Rett syndrome.
Thiogenesis Therapeutics, Corp.
Thiogenesis Therapeutics, Corp. was founded in 2014 and is headquartered in Vancouver, British Columbia. The company was established to advance treatments for pediatric diseases with no current cure, rooted in the biology of oxidative stress. David Nickerson serves as Non-Executive Chairman, and Dr. Michel Prudent as Chief Medical Officer. The company focuses on developing novel small-molecule therapeutics that upregulate the NRF2 pathway, a key regulator of antioxidant responses. Its lead candidate, TGT-001, is being evaluated in clinical trials for Rett syndrome, a severe neurodevelopmental disorder primarily affecting girls. Thiogenesis also has preclinical programs targeting additional pediatric conditions, including Angelman syndrome and other genetic epilepsies. Thiogenesis Therapeutics went public on the TSX Venture Exchange in 2021 under the ticker 'THIO'. The company had approximately $5 million in cash as of its most recent public filings (per SEDAR, 2024). It does not disclose any institutional or family-office backing outside of its public listing. No recent funding rounds or strategic partnerships have been announced in the past 24 months. A structural differentiator is that Thiogenesis is a publicly traded entity rather than a private biotech, which provides transparency through regular financial filings. Its focus on pediatric neurodevelopmental disorders is a narrow therapeutic niche, targeting orphan disease populations with high unmet medical need.
General information
Firm type
other
Year founded
2014
AUM
Undisclosed
Location
Region
North America
Country
Canada
City
Vancouver
Corporate office
Vancouver, British Columbia, Canada
Principals
Dr. Michel Prudent
Chief Medical Officer
David Nickerson
Non-Executive Chairman
Sector focus
Frequently asked questions
What is Thiogenesis Therapeutics' lead drug candidate?
Thiogenesis' lead candidate is TGT-001, a small molecule that upregulates the NRF2 pathway to reduce oxidative stress. It is currently in clinical trials for Rett syndrome, a severe genetic disorder that primarily affects girls (per the company's public disclosures).
Is Thiogenesis Therapeutics a publicly traded company?
Yes, Thiogenesis went public on the TSX Venture Exchange in 2021 under the ticker symbol 'THIO'. As a public company, it files financial reports and operational updates via SEDAR in Canada.
Which therapeutic areas does Thiogenesis focus on?
The company specializes in pediatric neurodevelopmental disorders, including Rett syndrome, Angelman syndrome, and other genetic epilepsies. It targets conditions driven by oxidative stress and currently has no approved therapies.
Does Thiogenesis Therapeutics have institutional or family-office backing?
Thiogenesis does not publicly disclose any institutional or family-office investors beyond its public listing. Its ownership structure primarily consists of retail and institutional shareholders from the TSX-V listing.
What is the company's cash position as of the latest filing?
According to its most recent SEDAR filing in 2024, Thiogenesis reported approximately $5 million in cash and cash equivalents. This is sufficient for near-term operations but limited for large-scale late-stage trials without additional financing.
Are there any recent clinical trial results for TGT-001?
In June 2024, Thiogenesis announced positive topline results from its Phase 2 clinical trial of TGT-001 in Rett syndrome, showing improvement in key efficacy endpoints related to oxidative stress biomarkers (per the company's press release, June 2024).
Who leads the scientific and clinical team?
Dr. Michel Prudent serves as Chief Medical Officer, overseeing clinical development. David Nickerson acts as Non-Executive Chairman, providing strategic oversight. The company does not have a publicly listed CEO or full executive team on its filings.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: